Editas Medicine (EDIT) news
Recent news
Editas Medicine Q2 collaboration and other research and development revenue USD 11.9 million
AInvest Wire · Aug 5, 2026Editas Medicine Q2 EPS USD -0.15
AInvest Wire · Aug 5, 2026Editas Medicine: offering 55.5M shares of common stock
Editas Medicine Inc. (NASDAQ: EDIT) has announced plans to offer 55.5 million shares in a public offering. The offering is intended to raise capital to support the company's ongoing research and development efforts in the field of genome editing. The company has also granted the underwriters a…
AInvest Wire · May 26, 2026Editas Medicine: warranty exercise price $3.50 per share
AInvest Wire · May 26, 2026Editas Medicine prices offering at $2.25 per common stock share
Editas Medicine, Inc. (NASDAQ: EDIT), a clinical-stage genome editing company, has priced its recent public offering of common stock at $2.25 per share. The offering is part of a broader capital-raising initiative aimed at supporting the company’s ongoing research and development efforts in the…
AInvest Wire · May 26, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.